Oncology
Addressing the full continuum of cancer
From early-stage, resected cancers, where the disease carries a high risk of recurrence, to locally advanced/unresectable or metastatic cancers, our oncology strategy encompasses the entire spectrum of cancer. By combining compounds with synergistic or complementary mechanisms of action that focus on the fundamental drivers of the disease, we work to create space for curative approaches.
Our goal is to develop innovative treatment options for all stages of cancer to set new standards that have the potential to address the fundamental challenges in oncology.
Our therapeutic modalities
mRNA cancer immunotherapies
Our investigational portfolio includes mRNA-based therapeutic approaches aimed at inducing immune responses against cancer targets that are either individual for each patient (iNeST) or associated with a tumor type (FixVac).
Next-generation immunomodulators
Our candidates are designed to modulate the patient's immune response to cancer, promoting a thorough and durable antitumor effect.
Targeted therapies
We are researching potent and precise therapeutic approaches such as cell therapies and antibody-drug conjugates (“ADCs”) that may supplement or replace standard chemotherapy. ADCs are a key component for novel combinations with other compounds in our oncology pipeline because they may work synergistically with other therapies to enhance their effectiveness against cancer.
Explore more
Pipeline
Clinical trials
